Emerging in the field of obesity management, retatrutide presents a distinct approach. Unlike many existing medications, retatrutide functions as a twin agonist, concurrently engaging both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) receptors. The concurrent engagement encourages several advantageous effects,